0001127602-24-017725.txt : 20240604 0001127602-24-017725.hdr.sgml : 20240604 20240604165300 ACCESSION NUMBER: 0001127602-24-017725 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240531 FILED AS OF DATE: 20240604 DATE AS OF CHANGE: 20240604 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GAYNOR RICHARD CENTRAL INDEX KEY: 0001741284 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35299 FILM NUMBER: 241019036 MAIL ADDRESS: STREET 1: C/O NEON THERAPEUTICS STREET 2: 40 ERIE STREET, SUITE 110 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Alkermes plc. CENTRAL INDEX KEY: 0001520262 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 981007018 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: CONNAUGHT HOUSE STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN 4 STATE: L2 ZIP: 00000 BUSINESS PHONE: 00-353-1-772-8000 MAIL ADDRESS: STREET 1: CONNAUGHT HOUSE STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN 4 STATE: L2 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: ANTLER SCIENCE TWO PLC DATE OF NAME CHANGE: 20110804 FORMER COMPANY: FORMER CONFORMED NAME: Antler Science Two Ltd DATE OF NAME CHANGE: 20110509 4 1 form4.xml PRIMARY DOCUMENT X0508 4 2024-05-31 0001520262 Alkermes plc. ALKS 0001741284 GAYNOR RICHARD CONNAUGHT HOUSE 1 BURLINGTON ROAD DUBLIN 4 Ireland 1 0 Non Qualified Stock Option (Right to Buy) 20.81 2023-11-17 5 J 0 E 1236 20.81 A 2029-12-04 Ordinary Shares 1236 63036 D Non Qualified Stock Option (Right to Buy) 20.81 2023-11-17 5 J 0 E 224 20.81 A 2029-12-04 Ordinary Shares 224 11424 D Non Qualified Stock Option (Right to Buy) 16.52 2023-11-17 5 J 0 E 256 16.52 A 2030-05-20 Ordinary Shares 256 13079 D Non Qualified Stock Option (Right to Buy) 18.45 2023-11-17 5 J 0 E 230 18.45 A 2030-12-02 Ordinary Shares 230 11739 D Non Qualified Stock Option (Right to Buy) 24.24 2023-11-17 5 J 0 E 313 24.24 A 2031-06-14 Ordinary Shares 313 15990 D Non Qualified Stock Option (Right to Buy) 30.86 2023-11-17 5 J 0 E 231 30.86 A 2032-07-07 Ordinary Shares 231 11785 D Non Qualified Stock Option (Right to Buy) 30.72 2023-11-17 5 J 0 E 254 30.72 A 2024-06-29 2033-06-29 Ordinary Shares 254 12986 D Restricted Stock Unit Award 2023-11-17 5 J 0 E 119 A 2024-06-29 Ordinary Shares 119 6104 D Restricted Stock Unit Award 2024-05-31 4 A 0 8013 0 A 2025-05-31 Ordinary Shares 8013 8013 D Non Qualified Stock Option (Right to Buy) 23.40 2024-05-31 4 A 0 17492 0 A 2025-05-31 2034-05-31 Ordinary Shares 17492 17492 D Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. These options are fully vested in accordance with their terms. Shares subject to the stock option award vest and become exercisable in full on 6/29/2024. Each restricted stock unit represents a contingent right to receive one ordinary share. Shares subject to the restricted stock unit award vest in full on 6/29/2024. Shares subject to the restricted stock unit award vest in full on 5/31/2025. Shares subject to the stock option award vest and become exercisable in full on 5/31/2025. EXHIBIT LIST: Exhibit 24.1 - Power of Attorney /s/ Shantale Greenson, attorney-in-fact for Richard Gaynor 2024-06-04 EX-24 2 doc1.txt POWER OF ATTORNEY (PUBLIC): POA FEB 2024 EXHIBIT 24.1 POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS, that the undersigned hereby revokes all powers of attorney relating to the following matters and constitutes and appoints each of Samuel Parisi, Shantale Greenson, Stephanie Roche, Rob Puopolo and Jeffrey Geary, and any one of them acting singly, as true and lawful attorneys-in-fact and agents, with the full power of substitution and resubstitution, for the undersigned and in the undersigned?s name, place and stead, in any and all capacities (until revoked in writing) to: (1) prepare, execute in the undersigned?s name and on the undersigned?s behalf, and submit to the U.S. Securities and Exchange Commission (?SEC?) a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?) or any rules or regulations of the SEC; (2) prepare, execute, acknowledge, deliver and file for and on behalf of the undersigned, in the undersigned?s capacity as an officer and/or director of Alkermes plc, an Irish corporation, or its subsidiaries (together, the ?Company?), Forms 3, 4, and 5 (including any amendments thereto) in accordance with Section 16(a) of the Exchange Act and the rules thereunder; (3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to prepare, execute, acknowledge, deliver and file any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority including, if necessary, non-U.S. regulators; (4) seek or obtain, as the undersigned?s representative and on the undersigned?s behalf, information on transactions in the Company?s securities from any third party, including without limitation brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned and approves and ratifies any such release of information; and (5) perform any and all other acts which in the discretion of such attorney-in-fact are necessary or desirable for and on behalf of the undersigned in connection with the foregoing. The undersigned acknowledges that: (1) this Power of Attorney authorizes, but does not require, each such attorney-in-fact to act in his or her discretion on information provided to such attorney-in-fact without independent verification of such information; (2) any documents prepared and/or executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney will be in such form and will contain such information and disclosure as such attorney-in-fact, in his or her discretion, deems necessary or desirable; (3) neither the Company nor such attorneys-in-fact assume any liability or obligation for the undersigned in connection with the matters covered hereby, including without limitation (i) any liability for the undersigned?s responsibility to comply with the requirements of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and (4) this Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned?s obligations under the Exchange Act, including without limitation the reporting requirements under Section 16 of the Exchange Act. The undersigned undertakes and agrees to indemnify the attorneys-in-fact against all actions, claims, demands, proceedings, costs, charges, expenses and other liabilities whatsoever which may be made against the attorneys-in-fact, or for which the attorneys-in-fact may become liable, by reason of acting pursuant to this Power of Attorney and the attorneys-in-fact shall not be liable to the undersigned for any loss or damage occurring as a result of any act or omission made by the attorneys-in-fact in good faith by reason of acting pursuant to this Power of Attorney. The undersigned hereby gives and grants the foregoing attorneys-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, hereby ratifying all that such attorneys-in-fact of, for and on behalf of the undersigned, will lawfully do or cause to be done by virtue of this Power of Attorney. This Power of Attorney will remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned?s holdings of and transactions in securities issued by Alkermes plc, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. This Power of Attorney will be governed by the laws of the State of New York, without regard to its choice of law provisions. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date set forth below. Date: February 5, 2024 Signed: /s/ Richard Gaynor Name: Richard Gaynor